Actavis Blood Pressure Pill Not Backed by U.S. Advisers
This article is for subscribers only.
Actavis Plc failed to win the backing of U.S. regulatory advisers for an experimental pill that combines two existing drugs to lower high blood pressure.
The combination pill shouldn’t be approved to treat hypertension because it doesn’t provide a clinically meaningful benefit over the two drugs alone, Food and Drug Administration advisers said today at a meeting. The advisory panel voted 6 to 4 against recommending the treatment.